Development of miltefosine as an oral treatment for leishmaniasis

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 100, Issue SUPPL. 1, 2006, Pages

  Sindermann, H ^a   Engel, J ^a  

^a Zentaris GmbH   (Germany)

Author keywords

Alkyl phospholipid; Anticancer agent; Antileishmanial; Cutaneous leishmaniasis; Miltefosine; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CYTOCHROME P450; MILTEFOSINE; PLACEBO;

ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CLINICAL STUDY; CLINICAL TRIAL; COLOMBIA; CONTRACEPTION; DOG; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EMBRYOTOXICITY; EYE TOXICITY; FETOTOXICITY; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; INDIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MALE INFERTILITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; PANCYTOPENIA; PREGNANCY; RABBIT; RAT; REPRODUCTIVE TOXICITY; RETINA DISEASE; SKIN CANCER; SKIN LEISHMANIASIS; SPERMATOZOON ABNORMALITY; SPERMIOGRAM; TERATOGENICITY; TESTIS ATROPHY; TESTIS DISEASE; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VISCERAL LEISHMANIASIS;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION; DRUG-INDUCED LIVER INJURY; EYE DISEASES; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KIDNEY DISEASES; LEISHMANIASIS; LIVER DISEASES; PHOSPHORYLCHOLINE; PREGNANCY; RATS; TERATOGENS;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 33749338420     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.02.010     Document Type: Article

References (15)

1. Croft S.I., and Engel J. Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives. Trans. R. Soc. Trop. Med. Hyg. 100. Suppl. 1 (2006)
2. Dummer R., Krasovec M., Roger J., Sindermann H., and Burg G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J. Am. Acad. Dermatol. 29 (1993) 963-970
3. Hilgard P., Klenner T., Stekar J., Nossner G., Kutscher B., and Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer 33 (1997) 442-446
4. Leonard R., Hardy J., van Tienhoven G., Houston S., Simmonds P., David M., and Mansi J. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J. Clin. Oncol. 19 (2001) 4150-4159
5. Planting A.S., Stoter G., and Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer 29A (1993) 518-519
6. Pronk L.C., Planting A.S., Oosterom R., Drogendijk T.E., Stoter G., and Verweij J. Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. Eur. J. Cancer 30A (1994) 1019-1022
7. Smorenburg C.H., Seynaeve C., Bontenbal M., Planting A.S., Sindermann H., and Verweij J. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs 11 (2000) 825-828
8. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J., and Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 38 (2004) 1266-1272
9. Sundar S., Rosenkaimer F., Makharia M.K., Goyal A.K., Mandal A.K., Voss A., Hilgard P., and Murray H.W. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352 (1998) 1821-1823
10. Sundar S., Jha T.K., Thakur C.P., Bhattacharya S.K., and Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100 Suppl. 1 (2006)
11. Theischen M., Bornfeld N., Becher R., Kellner U., and Wessing A. Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium. Ger. J. Ophthalmol. 2 (1993) 113-115
12. Unger C., Sindermann H., Peukert M., Hilgard P., Engel J., and Eibl H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog. Exp. Tumor Res. 34 (1992) 153-159
13. Verweij J., Planting A., van der Burg M., and Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J. Cancer Res. Clin. Oncol. 118 (1992) 606-608
14. Verweij J., Krzemieniecki K., Kok T., Poveda A., van Pottelsberghe C., van Glabbeke M., and Mouridsen H. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult: an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur. J. Cancer 29A (1993) 208-209
15. Verweij J., Gandia D., Planting A.S., Stoter G., and Armand J.P. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur. J. Cancer 29A (1993) 778-779